Reduce Downstream Processing Costs for mAbs by Switching to Tosoh’s 2-Step Platform

contributed by Tosoh | 03/31/2020

Introduction

Downstream processing is responsible for up to 80 percent of the entire production costs of biotherapeutics. Given the current drive to reduce the cost of manufacturing for biological therapeutics, streamlining downstream processing is a necessity for chromatographers and process engineers.

In this study, we showcase the benefits of Tosoh’s 2-step process for the purification of monoclonal antibodies (mAb) in comparison to the standard industrial process. Combining high-performance Protein A capturing and a single polishing step on salt-tolerant anion exchange resin, we could reduce the downstream costs by 45 % and increase the production output by 58 %.

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.